Plant-Based Medicines Development Act: Federal Policy and Cannabis Research

Executive Summary

The Plant-Based Medicines Development Act, introduced in Congress in September 2026, aims to accelerate research and development of therapeutic compounds derived from cannabis, psilocybin mushrooms, and other botanical sources. The bipartisan legislation would establish a dedicated pathway within the Food and Drug Administration for plant-based medicine approval, create research grants totaling $50 million annually, and provide regulatory clarity for companies developing therapies from Schedule I substances. Sponsored by Representatives Earl Blumenauer (D-OR) and Nancy Mace (R-SC), the bill addresses longstanding barriers that have prevented academic institutions and pharmaceutical companies from conducting clinical trials on cannabis-derived medicines beyond CBD and synthetic cannabinoids. The legislation would not change the scheduling status of cannabis or psychedelics under the Controlled Substances Act, but would create exemptions for FDA-authorized research and streamline the Drug Enforcement Administration approval process for obtaining research-grade materials. Industry analysts estimate the plant-based medicine market could reach $12 billion by 2030 if regulatory pathways become clearer.

Why This Matters

The Plant-Based Medicines Development Act could unlock billions in pharmaceutical investment and expand treatment options for millions of patients with conditions ranging from PTSD to treatment-resistant depression. The legislation addresses a fundamental contradiction in U.S. drug policy: while 38 states have legalized medical cannabis and several have decriminalized psilocybin for therapeutic use, federal restrictions under 21 U.S.C. § 812 have created a research bottleneck that prevents rigorous clinical trials. Academic medical centers report waiting 12-18 months for DEA approval to conduct even small-scale studies, and the National Institute on Drug Abuse maintains a monopoly on cannabis cultivation for research purposes, producing material that researchers say does not reflect the potency or chemical diversity of products patients actually use. For patients, the stakes are immediate. Veterans groups estimate that 22 veterans die by suicide daily, with many unable to access MDMA-assisted therapy or psilocybin treatment protocols that have shown promise in clinical trials but remain federally prohibited. Cancer patients undergoing chemotherapy often turn to state-legal cannabis products for nausea and appetite stimulation, but physicians cannot provide evidence-based dosing guidance because FDA-approved research remains limited. The epilepsy community saw dramatic benefits when Epidiolex, a CBD-based medication, received FDA approval in 2018, but similar pathways for other cannabinoids like THCA, CBG, and CBN remain blocked. For the pharmaceutical industry, the bill represents a potential $12 billion market opportunity. Companies including Jazz Pharmaceuticals, GW Pharmaceuticals (now owned by Jazz), and Compass Pathways have invested hundreds of millions in plant-based medicine development but face regulatory uncertainty that deters venture capital investment. Multi-state operators in the cannabis industry see the legislation as a pathway to legitimacy and institutional investment, though some advocates worry that pharmaceutical pathways could undermine state-legal cannabis programs. The legislation also matters for federalism and state sovereignty. Oregon, Colorado, and California have created legal frameworks for psilocybin therapy, while Massachusetts and other states have decriminalized possession of entheogenic plants. The federal-state conflict creates legal jeopardy for patients, providers, and researchers operating under state law but violating federal statutes.

Background and History

The Plant-Based Medicines Development Act emerges from a 50-year struggle to reconcile drug prohibition with medical research, beginning with the Controlled Substances Act of 1970.

The Controlled Substances Act and Schedule I Classification (1970)

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., established five schedules of controlled substances based on medical utility and abuse potential. Congress placed cannabis in Schedule I, defined as substances with "no currently accepted medical use" and "high potential for abuse." The classification was intended as temporary pending a commission review, but became permanent despite the Shafer Commission's 1972 recommendation to decriminalize personal use. Psilocybin, psilocin, LSD, and mescaline received Schedule I classification in 1970 based on concerns about recreational use during the 1960s counterculture movement. The scheduling effectively ended a generation of psychiatric research that had produced more than 1,000 clinical papers on psychedelic-assisted therapy between 1950 and 1965.

The NIDA Monopoly and Research Barriers (1968-2016)

Since 1968, the National Institute on Drug Abuse has maintained the only federally legal cannabis cultivation facility, operated at the University of Mississippi. Researchers seeking to study cannabis must obtain approval from the DEA, the FDA, and NIDA—a triple-agency process that typically requires 12-18 months and frequently results in denial. The DEA has historically approved fewer than 20 private cultivation licenses for research purposes. In 2016, the DEA announced it would expand the number of licensed cannabis cultivators for research, but by 2026 had approved only three additional facilities beyond the University of Mississippi program. Researchers consistently report that NIDA-supplied cannabis contains THC levels of 8-12%, far below the 20-30% THC content of products available in state-legal markets, making research findings less applicable to real-world use.

State Medical Cannabis Programs (1996-2026)

California's Proposition 215 in 1996 established the first state medical cannabis program, creating a direct conflict with federal law. By 2026, 38 states and the District of Columbia had legalized medical cannabis, and 24 states had legalized adult-use cannabis. State programs created a $30 billion legal cannabis industry operating in violation of federal law, protected only by Justice Department enforcement discretion policies like the Cole Memorandum (2013-2018). The federal-state conflict created research paradoxes: universities receiving federal funding could not conduct cannabis research using state-legal products, even in states where such research was explicitly legal. The University of Colorado, Johns Hopkins University, and other institutions established private funding mechanisms to conduct observational studies, but could not perform FDA-quality clinical trials.

Epidiolex Approval and the CBD Exception (2018)

In June 2018, the FDA approved Epidiolex, a CBD-based medication for treating Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of childhood epilepsy. The approval marked the first FDA-authorized cannabis-derived medication and demonstrated that rigorous clinical trials on Schedule I substances were possible. GW Pharmaceuticals had conducted trials under an Investigational New Drug application, a pathway available to pharmaceutical companies but rarely used due to DEA restrictions on obtaining research material. The DEA subsequently rescheduled FDA-approved drugs containing CBD to Schedule V, but did not change the Schedule I status of the cannabis plant or other cannabinoids. The selective rescheduling created a two-tier system where pharmaceutical companies could develop specific compounds while broader research remained restricted.

Psychedelic Renaissance and FDA Breakthrough Therapy Designations (2017-2026)

Beginning in 2017, the FDA granted Breakthrough Therapy designation to MDMA-assisted therapy for PTSD (developed by the Multidisciplinary Association for Psychedelic Studies) and psilocybin therapy for treatment-resistant depression (developed by Compass Pathways and Usona Institute). The designations indicated that preliminary evidence showed substantial improvement over existing treatments and entitled sponsors to intensive FDA guidance. Phase 3 clinical trials for MDMA-assisted therapy reported 67% of participants no longer meeting PTSD diagnostic criteria after treatment, compared to 32% in the placebo group. Psilocybin trials for depression showed similar efficacy. However, the Schedule I status of these substances created logistical barriers: research sites required DEA-registered storage facilities, and therapists needed special training to handle controlled substances. Oregon became the first state to legalize psilocybin therapy in 2020 through Measure 109, establishing a licensed facilitator program that began operations in 2023. Colorado followed with Proposition 122 in 2022, and California considered similar legislation in 2024-2025. The state programs operated in legal gray areas, with facilitators potentially subject to federal prosecution despite state authorization.

Congressional Interest and Previous Legislative Attempts (2019-2026)

Representative Earl Blumenauer introduced multiple cannabis reform bills between 2019 and 2026, including provisions to deschedule cannabis and expunge prior convictions. The House passed cannabis banking reform (the SAFE Banking Act) five times between 2019 and 2025, but the Senate never brought the legislation to a vote. Bipartisan interest in veterans' access to psychedelic therapy grew after 2022, with Republican representatives like Dan Crenshaw (R-TX) and Nancy Mace (R-SC) supporting research expansion. The Plant-Based Medicines Development Act represents a narrower approach than comprehensive cannabis legalization, focusing specifically on pharmaceutical development pathways rather than broader criminal justice reform or adult-use legalization. Sponsors positioned the bill as a medical research initiative rather than a drug policy reform measure, aiming to attract bipartisan support.

Key Players

Congressional Sponsors

Representative Earl Blumenauer (D-OR) has championed cannabis reform since entering Congress in 1996, the same year Oregon legalized medical cannabis. He founded the Congressional Cannabis Caucus in 2017 and has introduced more than 20 cannabis-related bills. Representative Nancy Mace (R-SC) emerged as a Republican cannabis reform advocate in 2021, introducing the States Reform Act to federally deschedule cannabis while preserving state regulatory authority. The bipartisan co-sponsorship signals broader political viability than previous cannabis legislation. Additional co-sponsors include Representatives Barbara Lee (D-CA), Dave Joyce (R-OH), Alexandria Ocasio-Cortez (D-NY), and Matt Gaetz (R-FL), representing both progressive and libertarian-conservative perspectives. The Senate companion bill, expected in October 2026, will reportedly be sponsored by Senators Cory Booker (D-NJ) and Rand Paul (R-KY).

Food and Drug Administration

The FDA's Center for Drug Evaluation and Research would administer the new plant-based medicine pathway under the legislation. The agency has approved only four cannabis-related medications: Marinol and Syndros (synthetic THC), Cesamet (synthetic cannabinoid nabilone), and Epidiolex (plant-derived CBD). FDA Commissioner Dr. Robert Califf has stated that the agency evaluates drug applications based on safety and efficacy data regardless of political considerations, but has noted that Schedule I status creates "unnecessary barriers" to research. The FDA's Breakthrough Therapy designation for MDMA and psilocybin indicates agency openness to psychedelic medicine, but approval requires Phase 3 clinical trial data meeting the same standards as conventional pharmaceuticals. The Plant-Based Medicines Development Act would create a dedicated botanical drug pathway similar to the framework used for traditional Chinese medicine and Ayurvedic preparations, allowing approval based on whole-plant or whole-mushroom preparations rather than isolated compounds.

Drug Enforcement Administration

The DEA's Diversion Control Division regulates access to Schedule I substances for research purposes under 21 C.F.R. § 1301. The agency has historically taken a restrictive approach, denying most applications for private cannabis cultivation licenses and requiring researchers to obtain material from the NIDA monopoly source. DEA Administrator Anne Milgram testified to Congress in 2024 that the agency processes research applications "as expeditiously as possible" but must ensure "adequate safeguards against diversion." The Plant-Based Medicines Development Act would require the DEA to approve research registrations within 60 days and allow researchers to obtain plant material from state-licensed cultivators operating under FDA oversight, bypassing the NIDA monopoly. DEA opposition could complicate implementation, as the agency has regulatory authority independent of congressional intent.

National Institute on Drug Abuse

NIDA, part of the National Institutes of Health, has funded cannabis research since 1968 and operates the University of Mississippi cultivation facility. The institute's mission focuses on addiction and substance abuse rather than therapeutic applications, creating a structural bias toward research on harms rather than benefits. NIDA Director Dr. Nora Volkow has acknowledged this criticism and stated the institute supports expanded research on medical applications, but the agency's monopoly on legal cannabis supply has remained a bottleneck. The legislation would end NIDA's exclusive supply role for FDA-authorized research, allowing pharmaceutical companies and academic institutions to source material from DEA-registered cultivators producing strains relevant to their research questions. NIDA would retain its cultivation program for abuse-focused research.

Pharmaceutical Industry

Jazz Pharmaceuticals acquired GW Pharmaceuticals for $7.2 billion in 2021, gaining ownership of Epidiolex and a pipeline of cannabinoid medications. The company has invested more than $1 billion in cannabis drug development and would benefit substantially from streamlined regulatory pathways. Compass Pathways, a publicly traded company focused on psilocybin therapy, has raised $300 million in venture capital and completed Phase 2b trials showing efficacy for treatment-resistant depression. Other pharmaceutical players include Usona Institute (psilocybin for major depressive disorder), Atai Life Sciences (multiple psychedelic compounds), and Awakn Life Sciences (ketamine and MDMA therapy). These companies have advocated for regulatory reform while opposing broader legalization that would allow non-pharmaceutical access to psychedelics.

Multi-State Operators and Cannabis Industry

Large cannabis companies including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs operate in multiple state-legal markets but remain excluded from federal banking, capital markets, and interstate commerce. MSOs have invested millions in lobbying for federal reform, with mixed feelings about pharmaceutical pathways that could compete with state-legal products. The U.S. Cannabis Council and the National Cannabis Industry Association support the Plant-Based Medicines Development Act as a step toward federal legitimacy, but emphasize that pharmaceutical pathways should complement rather than replace state adult-use and medical programs. Some operators fear that FDA-approved medications could be used to justify federal preemption of state programs.

Patient Advocacy Organizations

Veterans groups including the Iraq and Afghanistan Veterans of America and the Veterans Cannabis Project have lobbied extensively for access to cannabis and psychedelic therapies for PTSD, traumatic brain injury, and chronic pain. The Multidisciplinary Association for Psychedelic Studies has funded MDMA research since 1986 and would be a primary beneficiary of streamlined approval pathways. Epilepsy Foundation advocacy was instrumental in Epidiolex approval, and the organization supports expanded cannabinoid research. Americans for Safe Access, founded in 2002, represents medical cannabis patients and supports the legislation while emphasizing that pharmaceutical pathways must not restrict access to whole-plant cannabis through state programs.

Legal and Regulatory Framework

The Plant-Based Medicines Development Act would create a new botanical drug pathway within existing FDA authority while requiring DEA cooperation on research access. The legislation amends the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.) to establish a Plant-Based Medicines Development Program within the FDA's Center for Drug Evaluation and Research. The program would operate similarly to the botanical drug pathway created in 2004, which has approved only two products (Veregen for genital warts and Fulyzaq for HIV-associated diarrhea) due to the difficulty of standardizing plant-based preparations.

Botanical Drug Pathway Provisions

The bill would allow sponsors to seek approval for whole-plant or whole-mushroom preparations without isolating single active compounds, provided they can demonstrate consistent chemical composition across batches. Sponsors must identify marker compounds for quality control and establish acceptable ranges of variation. For cannabis, this could mean standardizing ratios of THC, CBD, CBG, and terpenes rather than isolating pure THC. For psilocybin mushrooms, preparations could contain psilocybin, psilocin, baeocystin, and other naturally occurring compounds. The botanical pathway requires the same clinical trial evidence as conventional drugs—Phase 1 safety studies, Phase 2 proof-of-concept trials, and Phase 3 pivotal efficacy trials—but allows more flexibility in formulation. The FDA would establish guidance documents within 180 days of enactment specifying requirements for plant-based medicine applications.

DEA Research Registration Reforms

The legislation mandates that the DEA approve or deny research registrations within 60 days of application, compared to the current average of 12-18 months. Denials must include specific reasons and allow for administrative appeal. The bill authorizes researchers to obtain Schedule I plant materials from state-licensed cultivators that register with the DEA and meet Good Manufacturing Practice standards, ending the NIDA monopoly for FDA-authorized research. Researchers would still need DEA Schedule I licenses for their facilities, requiring secure storage and detailed record-keeping under 21 C.F.R. § 1301-1305. However, the bill creates a streamlined registration process for academic medical centers and pharmaceutical companies conducting FDA-authorized trials.

Research Grant Program

The act authorizes $50 million annually for competitive research grants administered by the National Institutes of Health. Priority areas include:

• Therapeutic applications of cannabinoids beyond CBD
• Psychedelic-assisted therapy for PTSD, depression, and addiction
• Comparative effectiveness of whole-plant versus isolated compounds
• Drug interactions and contraindications
• Optimal dosing and administration routes
• Long-term safety and efficacy

Grants would be available to academic institutions, pharmaceutical companies, and non-profit research organizations. The legislation specifies that at least 20% of funding must support research at minority-serving institutions and universities in states with legal cannabis programs.

Relationship to Controlled Substances Act

The Plant-Based Medicines Development Act does not change the Schedule I status of cannabis, psilocybin, or other substances under 21 U.S.C. § 812. Possession, cultivation, and distribution remain federal crimes except as specifically authorized for FDA-approved research and approved medications. This approach mirrors the Epidiolex precedent: the cannabis plant remains Schedule I, but FDA-approved CBD products were rescheduled to Schedule V. The legislation creates an explicit exemption from federal prosecution for researchers, sponsors, and patients participating in FDA-authorized clinical trials. State-licensed cultivators supplying research material would operate under federal exemption similar to hemp producers under the 2018 Farm Bill. However, recreational use and state-legal medical programs not involving FDA-approved products would remain in conflict with federal law.

Interstate Commerce and Banking Implications

FDA-approved plant-based medicines would be legal for interstate commerce under the Federal Food, Drug, and Cosmetic Act, allowing pharmaceutical distribution across state lines. This would create a two-tier system: FDA-approved products legal nationwide, and state-legal cannabis products prohibited from crossing state borders. The legislation does not address banking access for state-legal cannabis businesses, a separate issue covered by the proposed SAFE Banking Act. However, pharmaceutical companies developing FDA-approved plant-based medicines would have full access to banking, capital markets, and federal contracts.

State-by-State Breakdown

State cannabis and psychedelic programs create a patchwork of legal frameworks that the Plant-Based Medicines Development Act would not directly change but could influence through federal pharmaceutical pathways.

Oregon

Oregon legalized medical cannabis in 1998 and adult-use cannabis in 2014. Measure 109, approved in 2020, created the nation's first legal psilocybin therapy program, administered by the Oregon Health Authority. Licensed facilitators began offering psilocybin sessions in 2023 at approximately 20 licensed service centers. The program requires participants to complete preparation sessions, consume psilocybin under supervision, and participate in integration therapy. Possession limits for adult-use cannabis are two ounces in public, eight ounces at home. Oregon decriminalized personal possession of all drugs in 2020 through Measure 110, though the legislature partially repealed decriminalization in 2024 after public backlash.

Colorado

Colorado legalized medical cannabis in 2000 and adult-use in 2012, creating the first regulated adult-use market in 2014. Proposition 122 in 2022 legalized psilocybin and psilocin, with regulated therapy programs expected to launch in 2026. The measure also decriminalized possession of DMT, ibogaine, and mescaline (excluding peyote). Adult-use cannabis possession limits are one ounce in public, with no home possession limit specified. Colorado's Marijuana Enforcement Division regulates more than 1,000 licensed cannabis businesses generating $1.5 billion in annual sales.

California

California pioneered medical cannabis with Proposition 215 in 1996 and legalized adult-use through Proposition 64 in 2016. The state allows possession of one ounce in public and cultivation of six plants at home. California's cannabis market generates approximately $5 billion in annual legal sales, though illicit market sales are estimated at $8 billion. The state has not legalized psilocybin therapy, but Oakland, Santa Cruz, and San Francisco have decriminalized possession and cultivation of entheogenic plants. Legislation to create a state-regulated psilocybin program similar to Oregon's has been introduced multiple times but not passed.

Massachusetts

Massachusetts legalized medical cannabis in 2012 and adult-use in 2016, with retail sales beginning in 2018. Possession limits are one ounce in public, 10 ounces at home, and cultivation of six plants per person (12 per household). The Cannabis Control Commission regulates approximately 400 licensed businesses. Several cities including Cambridge, Somerville, and Northampton have decriminalized possession of entheogenic plants, but the state has not established a legal psilocybin therapy program.

New York

New York legalized medical cannabis in 2014 and adult-use in 2021 through the Marijuana Regulation and Taxation Act. The Office of Cannabis Management oversees licensing, with retail sales beginning in late 2022. Possession limits are three ounces in public, five pounds at home, and cultivation of three mature plants per person (six per household). New York has not legalized or decriminalized psilocybin. The state's medical program initially restricted smokable flower and limited qualifying conditions, but expanded significantly after adult-use legalization.

Ohio

Ohio legalized medical cannabis in 2016 with sales beginning in 2019. Adult-use legalization passed through citizen initiative (Issue 2) in November 2023, with retail sales beginning in August 2024. Possession limits are 2.5 ounces in public with home cultivation prohibited initially, though the legislature may authorize cultivation in future rule-making. Ohio's medical program serves approximately 300,000 registered patients. The state has not considered psilocybin legalization or decriminalization.

Florida

Florida legalized medical cannabis through Amendment 2 in 2016, creating one of the nation's largest medical programs with more than 800,000 registered patients. The state does not allow smokable flower for medical use (though this restriction was partially lifted in 2019) and prohibits home cultivation. Adult-use legalization appeared on the November 2024 ballot as Amendment 3, requiring 60% approval, but failed with 58% support. Florida has not considered psilocybin reform. The state's vertically integrated license structure limits the market to approximately 20 multi-state operators.

Texas

Texas operates a limited medical cannabis program (the Compassionate Use Program) established in 2015 and expanded in 2019 and 2021. The program allows low-THC cannabis (up to 1% THC) for specific qualifying conditions including epilepsy, PTSD, and cancer. The state has three licensed dispensing organizations. Adult-use cannabis remains illegal with criminal penalties, though several cities including Austin, Dallas, and San Antonio have adopted cite-and-release policies for small possession amounts. Texas has not considered psilocybin reform.

Federal Territories and Tribal Lands

The District of Columbia legalized medical cannabis in 2010 and adult-use possession and cultivation in 2014 through Initiative 71. However, congressional appropriations riders have blocked the district from establishing regulated adult-use sales, creating a "gifting" market where consumers purchase non-cannabis products and receive cannabis as a gift. Guam, the U.S. Virgin Islands, and the Northern Mariana Islands have legalized medical and adult-use cannabis. Puerto Rico operates a medical cannabis program established in 2015. Native American tribes have sovereign authority to establish cannabis policies on tribal lands regardless of state law. The Justice Department's 2014 guidance (rescinded in 2018 but informally followed) stated that tribes could operate cannabis programs if they met federal enforcement priorities. Dozens of tribes have established medical or adult-use programs, though banking access remains problematic.

Market and Business Implications

The Plant-Based Medicines Development Act could redirect billions in investment from state-legal cannabis operators to pharmaceutical companies while creating new opportunities for research-focused businesses. The U.S. cannabis industry generated approximately $30 billion in sales in 2025 across state-legal markets, but remains excluded from interstate commerce, federal banking, and capital markets due to Schedule I status. Multi-state operators trade on Canadian exchanges or over-the-counter markets at depressed valuations due to federal illegality. The industry faces effective tax rates exceeding 70% due to Internal Revenue Code Section 280E, which prohibits businesses trafficking in Schedule I substances from deducting ordinary business expenses.

Pharmaceutical Investment Flows

Jazz Pharmaceuticals' $7.2 billion acquisition of GW Pharmaceuticals in 2021 demonstrated institutional investor appetite for cannabis-derived medications operating within FDA approval pathways. Compass Pathways raised $300 million in venture capital and maintains a market capitalization exceeding $500 million despite having no approved products. Atai Life Sciences went public in 2021 at a $2.5 billion valuation. The Plant-Based Medicines Development Act would likely accelerate pharmaceutical investment by reducing regulatory uncertainty. Industry analysts estimate that 10-15 plant-based medicines could reach FDA approval by 2030 if the legislation passes, generating $8-12 billion in annual pharmaceutical sales. Therapeutic areas with the strongest commercial potential include:

• PTSD treatment (estimated 13 million U.S. adults affected, current pharmaceutical market $2 billion annually)
• Treatment-resistant depression (estimated 3 million U.S. adults, current market $1.5 billion)
• Chemotherapy-induced nausea (estimated 1.5 million patients annually, current market $1 billion)
• Chronic pain management (estimated 50 million U.S. adults, opioid alternative market potential $10+ billion)
• Epilepsy beyond Epidiolex-approved conditions (estimated 3.4 million U.S. patients)

Impact on Multi-State Operators

State-legal cannabis operators face mixed implications. FDA-approved plant-based medicines could provide a pathway to federal legality and institutional investment, but would require companies to conduct expensive clinical trials and meet pharmaceutical manufacturing standards. Most MSOs lack the capital and expertise for FDA approval processes, potentially ceding the pharmaceutical market to traditional drug companies. Some MSOs including Curaleaf and Green Thumb Industries have established pharmaceutical research divisions and could pursue FDA approval for specific products. However, the vertically integrated cultivation and retail model that dominates state markets differs fundamentally from pharmaceutical distribution through pharmacies and insurance reimbursement. The legislation could also create competitive pressure on state-legal markets. If FDA-approved cannabis medications become available through insurance with physician prescriptions, patients might prefer pharmaceutical products over dispensary purchases. This could reduce state-legal sales while expanding overall cannabis medicine access.

Wholesale and Cultivation Economics

Cannabis wholesale prices have declined dramatically as state markets mature, falling from $2,000-3,000 per pound in early medical markets to $500-800 per pound in mature adult-use states like Colorado and Oregon. Oversupply has driven some cultivators into bankruptcy and led to industry consolidation. FDA-approved research could stabilize cultivation economics by creating pharmaceutical demand for research-grade material meeting Good Manufacturing Practice standards. Pharmaceutical-grade cannabis commands premium pricing—the University of Mississippi charges researchers $1,500-2,000 per pound for material with 8-12% THC. Private cultivators producing 20-30% THC strains with consistent terpene profiles could charge $3,000-5,000 per pound to pharmaceutical sponsors. The legislation would create a new category of DEA-registered research cultivators operating under federal authority, potentially in states without legal cannabis programs. This could shift cultivation investment from state-legal markets to pharmaceutical supply chains.

Ancillary Business Opportunities

The plant-based medicine pathway would create opportunities for businesses providing clinical trial services, analytical testing, regulatory consulting, and pharmaceutical manufacturing. Contract research organizations specializing in botanical drug development could see substantial growth. Analytical laboratories capable of characterizing complex plant chemistries and ensuring batch-to-batch consistency would be essential for FDA approval. Real estate investors could develop specialized facilities meeting DEA security requirements and pharmaceutical manufacturing standards. Insurance companies could develop products covering clinical trial liability and product liability for plant-based medicines. Law firms specializing in FDA regulatory affairs and DEA compliance would see increased demand.

International Competitiveness

Canada legalized adult-use cannabis nationally in 2018 and has positioned itself as a center for cannabis pharmaceutical research. Canadian companies including Tilray, Canopy Growth, and Aurora Cannabis have invested heavily in medical research and international distribution. The European Union has authorized medical cannabis in Germany, the Netherlands, and other member states, creating a pharmaceutical market that U.S. companies cannot access due to federal prohibition. The Plant-Based Medicines Development Act could restore U.S. competitiveness in cannabis pharmaceutical development by allowing American companies to conduct research and seek FDA approval without violating federal law. FDA approval often serves as a global gold standard, facilitating international market access.

What Experts Say

Medical researchers, policy analysts, and industry leaders have expressed cautious optimism about the Plant-Based Medicines Development Act while noting implementation challenges. Dr. Sue Sisley, a physician and researcher who has conducted FDA-approved trials on cannabis for PTSD in veterans, said in a September 2026 interview that the legislation "addresses the most significant barrier to cannabis research—the absurd requirement that we obtain inferior research material from a single government source while patients use completely different products in state-legal markets." Dr. Sisley noted that her research team waited 18 months for DEA approval to begin trials and that the NIDA-supplied cannabis "bore no resemblance to what veterans actually consume." According to Dr. Matthew Johnson, a professor of psychiatry at Johns Hopkins University who has conducted psilocybin research for depression and smoking cessation, the bill "would accelerate the timeline for FDA approval of psychedelic therapies by years, potentially bringing effective treatments to millions of patients who have exhausted conventional options." Dr. Johnson emphasized that pharmaceutical pathways should complement rather than replace emerging state-regulated psilocybin therapy programs. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, stated that the organization supports the legislation but cautions that "pharmaceutical pathways must not become a justification for continued criminalization of personal cannabis use or restrictions on state-regulated medical programs." Armentano noted that FDA-approved medications typically cost substantially more than state-legal cannabis products and may not be accessible to uninsured patients. Industry analyst Matt Karnes of GreenWave Advisors said in a research note that the legislation "could unlock $10-15 billion in pharmaceutical investment over the next decade but may create a two-tier system where wealthy patients access FDA-approved medications while others rely on state-legal markets operating in federal legal limbo." Karnes estimated that FDA approval processes cost $50-100 million per medication, pricing out smaller cannabis companies. According to Dr. Nora Volkow, director of the National Institute on Drug Abuse, the agency "supports expanded research on therapeutic applications of cannabis and psychedelics" and would cooperate with implementation of the legislation. However, Dr. Volkow noted that NIDA's mission focuses on addiction and substance abuse, and that therapeutic research "may be more appropriately funded through other NIH institutes such as the National Institute of Mental Health or the National Cancer Institute." Veterans advocate Nick Etten, founder of the Veterans Cannabis Project, said the legislation "represents a critical step toward providing evidence-based treatment options for the 22 veterans who die by suicide every day" and that veterans' groups would lobby intensively for passage. Etten noted that many veterans prefer whole-plant cannabis over isolated compounds like Epidiolex because of the entourage effect, where multiple cannabinoids and terpenes work synergistically.

What's Next

The Plant-Based Medicines Development Act faces a multi-stage legislative process with uncertain prospects in a divided Congress, but could advance through committee hearings in late 2026. The House version of the bill was referred to the Energy and Commerce Committee's Subcommittee on Health, which has jurisdiction over FDA matters, and the Judiciary Committee's Subcommittee on Crime and Federal Government Surveillance, which oversees DEA policy. Committee hearings are expected in October or November 2026, where sponsors will present testimony from medical researchers, patient advocates, and pharmaceutical industry representatives. The Senate companion bill, expected to be introduced in October 2026 by Senators Cory Booker and Rand Paul, would be referred to the Health, Education, Labor and Pensions Committee and the Judiciary Committee. Senate consideration typically moves more slowly than House action, and the bill would need 60 votes to overcome a filibuster unless included in budget reconciliation legislation